Approach to Family Screening in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy


Anneline S.J.M. te Riele, MD, Cynthia A. James, PhD, Judith A. Groeneweg, MD, Abhishek C. Sawant, MD, Kai Kammers, PhD, Brittney Murray, MS, Crystal Tichnell, MGC, Jeroen F. van der Heijden, MD, PhD, Daniel P. Judge, MD, J. Peter van Tintelen, MD, PhD, Richard N.W. Hauer, MD, PhD, Hugh Calkins, MD, and Harikrishna Tandri, MD

Interuniversity Cardiology Institute of the Netherlands, Utrecht, the Netherlands Johns Hopkins University School of Medicine, Baltimore, MD

Eur Heart J 2015; in press

# ARVD/C

- Inherited cardiomyopathy
- Desmosomal mutations
- RV dysfunction
- Ventricular arrhythmias
- Sudden cardiac death
  - Risk of sudden cardiac death is highest early in disease course<sup>1</sup>



1. Bhonsale, .., Te Riele, et al. Eur Heart J 2015;36:847-55

# **Rationale and Objectives**

- Autosomal dominant inheritance with variable expressivity
- Family screening is recommended
  - Prior studies only evaluated disease penetrance<sup>1,2</sup>
  - No guidelines on screening strategy or risk stratification
- Objective:
  - Determine predictors of ARVD/C diagnosis
  - Optimize arrhythmic risk stratification among relatives of ARVD/C patients

1. Dalal et al. Circulation 2005;112:3823-32.

2. Groeneweg, ...., Te Riele, et al. Circ Cardiovasc Genet 2015;8:437-46.


# Study Design

- Population: 274 first-degree relatives of ARVD/C patients who underwent comprehensive cardiologic evaluation
  - ICIN and Johns Hopkins Hospital
  - 36.5 ± 18.9 years, 46% male
  - Grouped as parents (n=68), siblings (n=120), or children (n=86)
- Primary outcome:
  - ARVD/C diagnosis as per 2010 diagnostic Task Force Criteria (TFC)
    - Also ascertained TFC independent of family history
- Secondary outcome:
  - Composite of life-threatening ventricular arrhythmia

# Results – ARVD/C diagnosis

• 96/274 (35%) relatives fulfilled 2010 TFC of ARVD/C by last follow-up


	ARVD/C (n=96)	
Male	32 (33)	
Age at diagnosis (yrs)	36.3 ± 14.6	
Symptomatic	32 (33)	
Syncope	11 (12)	
Presyncope	7 (7)	
Palpitations	27 (27)	
Pathogenic mutation	75 (78)	
Generation		
Sibling	61 (63)	
Child	19 (20)	
Parent	16 (17)	



### Results – Incidence of new ARVD/C diagnosis

# Results – Predictors of ARVD/C Diagnosis

	Univariate		Multivariate				
	OR	p-value	OR	p-value			
Age at presentation (compared to 18-35 year age group)							
<18 years	0.19 (0.09-0.44)	<0.001	0.37 (0.14-0.93)	0.036			
35-50 years	0.57 (0.30-1.10)	0.093	0.74 (0.34-1.60)	0.443			
>50 years	0.29 (0.14-0.61)	0.001	0.51 (1.65-5.88)	0.122			
Male gender	0.44 (0.26-0.73)	0.002	0.45 (0.25-0.83)	0.010			
Symptomatic at presentation	9.39 (4.25-20.76)	<0.001	7.84 (3.23-19.06)	<0.001			
Pathogenic mutation	3.26 (1.85-5.75)	<0.001	3.81 (1.96-7.40)	<0.001			
Sibling	3.52 (2.09-5.91)	<0.001	3.11 (1.65-5.88)	<0.001			
Malignant family history	1.70 (0.97-2.96)	0.061	-	-			




Model statistics: Accuracy 78% (95% CI 73–83%)

# **Results – Risk Stratification**

- Once diagnosis is made, most important management decision is whether to implant an ICD
  - 2008 ACC/AHA/HRS guidelines (updated 2012): fulfilling TFC is class IIa indication for ICD implantation<sup>1</sup>
- Revised 2010 TFC:
  - First-degree relatives get major criterion for family history
  - Many ARVD/C relatives are diagnosed at an early stage with unknown SCD risk

## Results – Risk Stratification

- 21 (8%) subjects experienced an arrhythmic event
  - Mean follow-up 6.7 ± 3.8 years
  - 35.0 ± 14.7 years, 11 (52%) male
  - All diagnosed 4.2 (IQR 1.1-7.4) years prior to the event
    - All fulfilled 2010 TFC independent of family history



# Conclusion

- One-third of first-degree relatives develop ARVD/C
  - Siblings are at highest risk of disease
  - Highest yield of screening in 20-40 year age range
- A combination of symptoms, being a sibling, pathogenic mutation, and female gender accurately predicts manifest ARVD/C
- Fulfillment of TFC independent of family history is superior to conventional TFC for risk stratification purposes

# Acknowledgments

#### ICIN / Netherlands Heart Institute

Thomas Mast Judith Groeneweg Maarten-Jan Cramer Jeroen van der Heijden Dennis Dooijes Peter Loh Birgitta Velthuis Peter van Tintelen Pieter Doevendans Richard Hauer

### Johns Hopkins Hospital

Abhishek Sawant Aditya Bhonsale Neda Rastegar Binu Phillips Cindy James Brittney Murray Crystal Tichnell Stefan Zimmerman Ihab Kamel Hari Tandri Hugh Calkins





This work was performed during Dr. Te Riele's tenure as the Heart Rhythm Society Research Fellow in Honor of Mark Josephson and Hein Wellens

# Family Screening – Predictors of Events

- 21 (8%) subjects experienced an arrhythmic event
  - Mean follow-up 6.7 ± 3.8 years

	Overall (n=96)	No ventricular arrhythmia (n=75)	Ventricular arrhythmia (n=21)	p-value
Male	32 (33)	21 (28)	11 (52)	0.036
Age at presentation	36.3 ± 14.6	36.7 ± 14.7	35.0 ± 14.7	0.652
Symptomatic	32 (33)	18 (24)	14 (67)	<0.001
Mutation	75 (78)	56 (75)	19 (91)	0.121
Generation Sibling Parent Child	61 (64) 16 (17) 19 (20)	47 (63) 15 (20) 13 (17)	14 (67) 1 (5) 6 (29)	0.185
Malignant family history	31 (32)	26 (34)	5 (24)	0.347

# **Clinical Implications**

- Optimize ARVD/C family screening regimens
  - Specific age range for screening
  - Focus on siblings
  - Characteristics that are independently associated with ARVD/C
  - Hierarchically cluster these variables in a risk stratification paradigm
- Improved risk stratification in at-risk subjects
  - Identify subgroup that may benefit from prophylactic ICD implantation